Clinical Trial: Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Brief Summary: Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Detailed Summary:
Sponsor: Federal University of São Paulo

Current Primary Outcome: improvement of symptoms of conjunctivitis (pain relief) [ Time Frame: 6 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Federal University of São Paulo

Dates:
Date Received: April 29, 2011
Date Started: August 2009
Date Completion:
Last Updated: May 5, 2011
Last Verified: April 2011